Navigation Links
U.S. Patent and Trademark Office Issues Mylan's Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
Date:1/12/2009

PITTSBURGH, Jan. 12 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Dey L.P. has been issued several additional U.S. patents protecting the company's Perforomist(R) Inhalation Solution, a chronic obstructive pulmonary disease (COPD) treatment.

U.S. Patent No. 7,462,645 was issued Dec. 9, 2008, and is directed to treatment through the administration of a ready-to-use, storage stable composition of formoterol. This patent covers Dey's Perforomist(R) Solution, and its term extends until June 22, 2021. The patent will be listed in the "Orange Book," giving Dey four Orange Book-listed patents covering Perforomist Solution.

U.S. Patent Nos. 7,465,756 and 7,473,710 were issued Dec. 16, 2008, and Jan. 6, 2009, respectively. These patents are directed to compositions of "R-formoterol," a specific form of the formoterol molecule, and their use.

In addition, Dey has received a "Notice of Allowance" on yet another patent also directed to the use of R-formoterol. This patent is expected to issue shortly. Upon its issuance, Dey will possess seven patents directed to compositions of formoterol, R-formoterol and/or their uses.

Mylan's Vice Chairman and CEO Robert J. Coury stated: "We are very pleased with the recent issuance of these additional patents, which we believe only further bolster Dey's already strong intellectual property portfolio, and we will continue to aggressively protect and assert Dey's IP rights. Dey is currently pursuing a patent infringement lawsuit against Sepracor relating to its Brovana(R) product."

Dey also has additional pending U.S. patent applications directed to formoterol-containing compositions and their use in the treatment of respiratory conditions.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies and emergency care medicine. As the U.S. leader in sales of nebulized respiratory medication, Dey L.P. puts patients first through its development of innovative and affordable therapies. The Web sites for Dey L.P. include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.cyanokit.com, www.duoneb.com, www.epipen.com and www.perforomist.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
2. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
3. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
4. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
5. Procter & Gamble Reaches Settlement on Patent Infringement Lawsuit
6. SpectraScience Awarded U.S. Patent 7,469,160 for Its Unique Methods and Apparatus for Evaluating Image Focus
7. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
8. FreePatentsOnline Launches the CitePatents Program : Making it Easy for Bloggers and Journalists to Reference Patents, and Add Patent Search to Websites
9. HPS Files Patent for Mood-Enhancing Compound Naturally Found in Sea Coral
10. Kidnapped senior needed IU-patented home security system
11. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been ... to surgery, treatment, therapy and management. Regular exercise in proper environments has been ... despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to ... backed by giants including Accenture, GE Ventures, and Software AG , will ...
(Date:2/21/2017)... , ... February 21, 2017 , ... A February 6 ... gastric balloons for weight loss. It found that the treatments have led to significant ... patients, when compared to unassisted efforts. It also noted very few problematic results relating ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Research and Markets has announced the addition of ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/21/2017)... DUBLIN , Feb. 21, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Anthrax Drugs Price Analysis ... global Anthrax market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Anthrax market? ...
(Date:2/20/2017)... , Feb. 20, 2017 Provides understanding ... and agreements entered into by the worlds leading ... https://www.reportbuyer.com/product/3605699/ Description The Global Renal Failure ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
Breaking Medicine Technology: